Autopsy report · NCT01322815

A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI

“Poor accrual rate”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months after it had already started.
• Ran for about 5 years 2 months before it stopped.
• 11 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Georgetown University

Sponsor type

University, hospital or other

Conditions

Colon Cancer

Interventions

chemotherapy and GI-4000; GI-4000

Participants

11

Sites

1

Countries

United States

Trials that died the same way

• Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
  “Low accrual rate” (92% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (89% match in meaning)
• Pharmacology of Aminophylline for Acute Kidney Injury in Neonates
  “insufficient rate of accrual” (88% match in meaning)
• Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
  “Insufficient accrual rate” (86% match in meaning)
• Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
  “poor accrual” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.